1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Analysis & Statistics in the United States, May 2020

Cancer Analysis & Statistics in the United States, May 2020

1-30 of about 2000 reports

Tissue Diagnostics Market by Product, Technology, Disease, End User -Global Forecast to 2025

  • $ 4950
  • May 2020
  • 175 pages

The global tissue diagnostic market size is projected to register a CAGR of 6.5% during the forecast period. The global tissue diagnostics market is expected to reach USD 4.7 billion by 2025 from USD 3.4 ...

  • Cancer
  • North America
  • United States
  • Market Size
  • Roche Group

North America Breast Cancer Screening Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Test Type ; End User, and Countries

  • $ 3000
  • May 2020
  • 155 pages

The North America breast cancer screening was valued at US$ 2,064.26 million in 2019 and is projected to reach US$ 2,832.04 million by 2027; it is expected to grow at CAGR of 5.1% from 2020 to 2027. The ...

  • Cancer
  • Diagnostics
  • Health Services
  • Laboratory
  • United States

2020 US Tumor Marker Testing Market: Supplier Shares, Volume and Sales Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, Opportunities for Suppliers

  • $ 2850
  • May 2020
  • 620 pages

2020 US Tumor Marker Testing Market: Supplier Shares, Volume and Sales Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, Opportunities for Suppliers High ...

  • Cancer
  • United States
  • Demand

Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast—2030

  • $ 4750
  • May 2020
  • 200 pages

‘Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the PD-L1 NSCLC ,historical ...

  • Cancer
  • Lung Cancer
  • Pathology
  • Therapy
  • United States

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC)-Market Insights, Epidemiology and Market Forecast—2030

  • $ 4750
  • May 2020
  • 200 pages

‘Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC)-Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the EGFR NSCLC, historical ...

  • Cancer
  • Lung Cancer
  • Pathology
  • United States
  • Market Size

Cellular-mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) -Market Insights, Epidemiology and Market Forecast—2030

  • $ 4750
  • May 2020
  • 200 pages

‘Cellular-mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) -Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding ...

  • Cancer
  • Lung Cancer
  • Pathology
  • Therapy
  • United States

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) -Market Insights, Epidemiology and Market Forecast—2030

  • $ 4750
  • May 2020
  • 200 pages

‘BRAF Mutated Non-small Cell Lung Cancer (NSCLC) -Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the BRAF Mutated NSCLC, historical and forecasted ...

  • Cancer
  • Lung Cancer
  • Pathology
  • United States
  • Forecast

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)-Market Insights, Epidemiology and Market Forecast to 2030

  • $ 4750
  • May 2020
  • 200 pages

‘Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)-Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the ALK NSCLC, historical and ...

  • Cancer
  • Lung Cancer
  • Pathology
  • United States
  • Market Size

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC)— Epidemiology Forecast to 2030

  • $ 2850
  • May 2020
  • 100 pages

‘Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC)— Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted EGFR-NSCLC ...

  • Cancer
  • Lung Cancer
  • Pathology
  • Germany
  • United States

Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2030

  • $ 2850
  • May 2020
  • 100 pages

‘Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted PD-L1 NSCLC ...

  • Cancer
  • Lung Cancer
  • Pathology
  • Germany
  • United States

Cellular-mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC)- Epidemiology Forecast to 2030

  • $ 2850
  • May 2020
  • 100 pages

‘Cellular-mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical ...

  • Cancer
  • Lung Cancer
  • Pathology
  • United Kingdom
  • United States

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2030

  • $ 2850
  • May 2020
  • 100 pages

‘BRAF Mutated Non-small Cell Lung Cancer (NSCLC)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted BRAF Mutated NSCLC epidemiology ...

  • Cancer
  • Lung Cancer
  • Pathology
  • United Kingdom
  • United States

Anaplastic lymphoma kinase Non Small Cell Lung Cancer (ALK-NSCLC) - Epidemiology Forecast to 2030

  • $ 2850
  • May 2020
  • 100 pages

‘Anaplastic lymphoma kinase-Non Small Cell Lung Cancer (ALK-NSCLC)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted ALK NSCLCepidemiology ...

  • Cancer
  • Lung Cancer
  • Pathology
  • Germany
  • United States

Hormone Receptor (HR) positive/ Human Epidermal Receptor 2 (HER2) negative Breast Cancer-Market Insights, Epidemiology and Market Forecast–2030

  • $ 6950
  • May 2020
  • 200 pages

‘Hormone Receptor (HR) positive/ Human Epidermal Receptor 2 (HER2) negative Breast Cancer-Market Insights, Epidemiology and Market Forecast–2030’ report delivers an in-depth understanding of the ...

  • Breast Cancer
  • Cancer
  • Therapy
  • United States
  • Market Size

Cancer Cachexia (CC) – Market Insights, Epidemiology, and Market Forecast—2030

  • $ 6950
  • May 2020
  • 167 pages

‘Cancer Cachexia (CC) – Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Cancer Cachexia (CC), historical and forecasted epidemiology as ...

  • Cancer
  • Pathology
  • Therapy
  • United States
  • Market Size

Small Cell Lung Cancer (SCLC)-Market Insights, Epidemiology and Market Forecast-2030

  • $ 6950
  • May 2020
  • 200 pages

‘Small Cell Lung Cancer (SCLC)-Market Insights, Epidemiology and Market Forecast-2030’ report delivers an in-depth understanding of the SCLC, historical and forecasted epidemiology as well as the SCLC ...

  • Cancer
  • Lung Cancer
  • Therapy
  • United States
  • Market Size

Global Diagnostics Partnering Terms and Agreements 2014-2020

  • $ 3495
  • May 2020
  • 1000 pages

The Global Diagnostics Partnering 2014-2020 report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading companies. Comprehensive ...

  • Cancer
  • Medical Biotechnology
  • Therapy
  • United States
  • Demand

Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2020

  • $ 3495
  • May 2020
  • 300 pages

The Global Cancer Monoclonal Antibody Partnering 2014-2020: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals ...

  • Cancer
  • Medical Biotechnology
  • Therapy
  • United States
  • Demand

Global Vaccine Partnering Terms and Agreements 2014-2020: Deal trends, players and financials

  • $ 3495
  • May 2020
  • 400 pages

The Global Vaccine Partnering Terms and Agreements 2014-2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and ...

  • Cancer
  • Hospital
  • Therapy
  • United States
  • Social Conditions

Global Oncology Partnering 2014-2020: Deal trends, players and financials

  • $ 3495
  • May 2020
  • 2500 pages

The Global Oncology Partnering 2014-2020: Deal trends, players and financials report provides an understanding and access to the oncology partnering deals and agreements entered into by the worlds leading ...

  • Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • Demand

Pheochromocytoma - Pipeline Review, H1 2020

  • $ 2000
  • April 2020
  • 112 pages

Pheochromocytoma - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Pheochromocytoma - Pipeline Review, H1 2020, provides an overview of the Pheochromocytoma ...

  • Cancer
  • Renal Cancer
  • Therapy
  • United States
  • Company Operations

Retinoblastoma - Pipeline Review, H1 2020

  • $ 2000
  • April 2020
  • 67 pages

Retinoblastoma - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Retinoblastoma - Pipeline Review, H1 2020, provides an overview of the Retinoblastoma ...

  • Cancer
  • Therapy
  • United States
  • Product Initiative
  • Cellceutix Corporation

Essential Thrombocythemia - Pipeline Review, H1 2020

  • $ 2000
  • April 2020
  • 115 pages

Essential Thrombocythemia - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Essential Thrombocythemia - Pipeline Review, H1 2020, provides an overview ...

  • Blood Disease
  • Cancer
  • United States
  • Product Initiative
  • Incyte Corporation

Cathepsin L1 - Pipeline Review, H1 2020

  • $ 3500
  • April 2020
  • 33 pages

Cathepsin L1 - Pipeline Review, H1 2020 Summary Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Cathepsin L, a lysosomal endopeptidase is a member of the papain-like family ...

  • Cancer
  • Therapy
  • United States
  • World
  • Product Initiative

Histone Deacetylase 3 - Pipeline Review, H1 2020

  • $ 3500
  • April 2020
  • 105 pages

Histone Deacetylase 3 - Pipeline Review, H1 2020 Summary Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Histone deacetylase 3 is an enzyme encoded by the HDAC3 gene. Histone deacetylation ...

  • Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

Estrogen Receptor Beta - Pipeline Review, H1 2020

  • $ 3500
  • April 2020
  • 78 pages

Estrogen Receptor Beta - Pipeline Review, H1 2020 Summary Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) pipeline Target constitutes close to 20 molecules. ...

  • Cancer
  • Hormone
  • Therapy
  • United States
  • Product Initiative

Retinoic Acid Receptor Alpha - Pipeline Review, H1 2020

  • $ 3500
  • April 2020
  • 76 pages

Retinoic Acid Receptor Alpha - Pipeline Review, H1 2020 Summary Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Retinoic acid receptor alpha ...

  • Cancer
  • Leukemia
  • United States
  • Product Initiative
  • Syros Pharmaceuticals, Inc.

Histone Deacetylase 2 - Pipeline Review, H1 2020

  • $ 3500
  • April 2020
  • 145 pages

Histone Deacetylase 2 - Pipeline Review, H1 2020 Summary According to the recently published report ’Histone Deacetylase 2 - Pipeline Review, H1 2020’; Histone Deacetylase 2 (Transcriptional Regulato ...

  • Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

Hepatocyte Growth Factor - Pipeline Review, H1 2020

  • $ 3500
  • April 2020
  • 80 pages

Hepatocyte Growth Factor - Pipeline Review, H1 2020 Summary Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 15 molecules. The latest report Hepatocyte ...

  • Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • AnGes MG, Inc.

Global Veterinary Oncology Market By Animal Type By Therapy By Cancer Type By Region, Industry Analysis and Forecast, 2020 - 2026

  • $ 3600
  • April 2020
  • 209 pages

The Global Veterinary oncology Market size is expected to reach $369.2 Million by 2026, rising at a market growth of 13.2% CAGR during the forecast period. Cancer is one of the main causes of morbidity ...

  • Cancer
  • Oncology
  • Therapy
  • United States
  • Market Size

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on